ArticleJournal of clinical medicine2019
Associations of Plasma 3-Methylhistidine with Frailty Status in French Cohorts of the FRAILOMIC Initiative.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- FIA-MS/MS-Based Targeted Metabolomics of Amino Acids and Acylcarnitines Uncovers Network-Level Metabolic Reprogramming in Chronic Kidney Disease.Biomedicines · 2026Article
- Novel biomarkers for sarcopenia: a narrative review.Journal of orthopaedic surgery and research · 2026Review
- Correlation between oxidative stress and inflammation with metabolomics profile in skeletal muscle of ageing animal model and its modulation by tocotrienol-rich fraction.British journal of biomedical science · 2026Article
- Protective association of renin-angiotensin system inhibitor use with skeletal muscle wasting in diabetic heart failure.Journal of diabetes investigation · 2026Article
- Frailty and sarcopenia metabolomic signatures in kidney transplant candidates: the FRAILMar study.Clinical kidney journal · 2025Article
- Article
- Changes in muscle quality and biomarkers of neuromuscular junctions and muscle protein turnover following 12 weeks of resistance training in older men.Biology of sport · 2024Article
- Gut microbiome composition and metabolic activity in women with diverticulitis.Nature communications · 2024Article
- Cross-sectional analysis of healthy individuals across decades: Aging signatures across multiple physiological compartments.Aging cell · 2024Article
- Relationship between Hydration Status and Muscle Catabolism in the Aged Population: A Cross-Sectional Study.Nutrients · 2023Observational
- Moderate protein intake percentage in mice for maintaining metabolic health during approach to old age.GeroScience · 2023Article
- Article
- Amino Acid Profiles in Older Adults with Frailty: Secondary Analysis from MetaboFrail and BIOSPHERE Studies.Metabolites · 2023Article
- Frailty is characterized by biomarker patterns reflecting inflammation or muscle catabolism in multi-morbid patients.Journal of cachexia, sarcopenia and muscle · 2023Article
- Nutritional and Nutrition-Related Biomarkers as Prognostic Factors of Sarcopenia, and Their Role in Disease Progression.Diseases (Basel, Switzerland) · 2022Review
- South Asian Working Action Group on SARCOpenia (SWAG-SARCO) - A consensus document.Osteoporosis and sarcopenia · 2022Review
- Serum and Fecal Amino Acid Profiles in Cats with Chronic Kidney Disease.Veterinary sciences · 2022Article
- Review
- A Pound of Flesh: What Cachexia Is and What It Is Not.Diagnostics (Basel, Switzerland) · 2021Review
- Salivary Metabolomics for Prognosis of Oral Squamous Cell Carcinoma.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Frailty and sarcopenia are characterized by a loss of muscle mass and functionality and are diagnosed mainly by functional tests and imaging parameters. However, more muscle specific biomarkers are needed to improve frailty diagnosis. Plasma 3-methylhistidine (3-MH), as well as the 3-MH-to-creatinine (3-MH/Crea) and 3-MH-to-estimated glomerular filtration rate (3-MH/eGFR) ratios might support the diagnosis of frailty. Therefore, we investigated the cross-sectional associations between plasma 3-MH, 3-MH/Crea and 3-MH/eGFR with the frailty status of community-dwelling individuals (>65 years). 360 participants from two French cohorts of the FRAILOMIC initiative were classified into robust, pre-frail and frail according to Fried's frailty criteria. General linear models as well as bivariate and multiple linear and logistic regression models, which were adjusted for several confounders, were applied to determine associations between biomarkers and frailty status. The present study consisted of 37.8% robust, 43.1% pre-frail and 19.2% frail participants. Frail participants had significantly higher plasma 3-MH, 3-MH/Crea and 3-MH/eGFR ratios than robust individuals, and these biomarkers were positively associated with frailty status. Additionally, the likelihood to be frail was significantly higher for every increase in 3-MH (1.31-fold) and 3-MH/GFR (1.35-fold) quintile after adjusting for confounders. We conclude that 3-MH, 3-MH/Crea and 3-MH/eGFR in plasma might be potential biomarkers to identify frail individuals or those at higher risk to be frail, and we assume that there might be biomarker thresholds to identify these individuals. However, further, especially longitudinal studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.